Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.74 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94129 | 0.88 | ABCB11 (0.58) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL30777846 | 0.88 | ABCB11 (0.78) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL24249 | 0.88 | ABCB11 (0.78) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747734 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747027 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL42390 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9998546 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11726346 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11168965 | 0.86 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL9747268 | 0.86 | ABCB11 (0.63) | ABCB11LMNAPTGS1ADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0221753-B1 | TRANSDERMAL TREATMENT FOR PAIN AND INFLAMMATION WITH 2-AMINO-3-AROYLBENZENEACETIC ACIDS, SALTS AND ESTERS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-08 | — | — | EP | claimed |
| US-4683242-A | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-07-28 | — | — | US | claimed |
| EP-0221753-A2 | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-05-13 | — | — | EP | claimed |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | disclosed |
| EP-1309322-B1 | USE OF 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISORDERS | ALCON INC (CH) | 2006-06-21 | — | — | EP | disclosed |
| CN-1649575-A | Method for treating vascular endothelial growth factor mediated vascular disorders with amfenac or nepafenac | ALCON INC (CH) | 2005-08-03 | — | — | CN | disclosed |
| US-20050143468-A1 | Method of treating vascular endothelial growth factor mediated vascular disorders | ALCON, INC. (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1507522-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | Alcon, Inc. (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2003092669-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | ALCON, INC. (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-4568695-A | ANTIINFLAMMATORY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-02-04 | — | — | US | disclosed |
| US-4529737-A | Analgesic and anti-inflammatory arylalkanoic acid phthalidyl esters and pharmaceutical compositions thereof | RESFAR S.R.I. (IT) | 1985-07-16 | — | — | US | disclosed |
| US-4455298-A | MOLLUSC EXTRACT | MCFARLANE STUART J (NZ) | 1984-06-19 | — | — | US | disclosed |
| EP-0010061-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT | Mc Farlane, Stuart John (NZ) | 1983-07-13 | — | — | EP | disclosed |
| EP-0010061-A1 | Pharmaceutical preparations containing a mollusc extract | Mc Farlane, Stuart John (NZ) | 1980-04-16 | — | — | EP | disclosed |
| EP-0007572-A1 | Pharmaceutical mixtures containing an amantadine compound | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
| US-4182774-A | Method of inhibiting blood platelet aggregation with 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof | A. H. ROBINS COMPANY, INCORPORATED (US) | 1980-01-08 | — | — | US | disclosed |
| US-4126635-A | ANTICHOLESTEROL, BLOOD PLATELET AGGREGATION INHIBITION | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-11-21 | — | — | US | disclosed |
| US-4045576-A | ANTI-INFLAMMATORY METHODS USING 2-AMINO-3-(5- AND 6-)BENZOYLPHENYLACETIC ACIDS, ESTERS AND METAL SALTS THEREOF AND THE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | ABCB11 4560/4885LMNA 4239/4885PTGS1 13/4885 |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | ABCB11 3404/4885LMNA 655/4885PTGS1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.